Jazz Pharmaceuticals plc has announced that the European Commission has granted conditional marketing authorization for Ziihera® (zanidatamab) for the treatment of advanced HER2-positive biliary tract cancer $(BTC.AU)$. This authorization, based on positive results from the HERIZON-BTC-01 Phase 2b trial, marks a significant milestone as Ziihera becomes the first HER2-targeted therapy approved in the European Union specifically for this patient population. The approval applies to all EU Member States, as well as Iceland, Norway, and Liechtenstein. This development provides a new targeted monotherapy option for patients who have limited treatment alternatives and highlights the importance of HER2 testing in BTC to identify eligible patients for biomarker-driven treatments.